Pulmonx
Glen French is an accomplished executive with extensive experience in the medical technology sector. Currently serving as a Member of the Board of Directors and CEO at Pulmonx Corporation since December 2014, Glen French has also contributed as an Advisor at Mach Ventures since January 2013. Previous leadership roles include Executive Chairman at Levita Magnetics and President of Pulmonary Endoscopy at Boston Scientific Corporation. Glen French was a co-founder of both Asthmatx and Broncus Technologies, holding the position of CEO at both companies. Additionally, Glen French served as Director and Co-Founder at NDO Surgical and held a marketing leadership role at C.R. Bard's Davol Surgical Division. Glen French holds a Master’s in Business Administration from The Wharton School and a Bachelor of Arts from Dartmouth College.
This person is not in any teams
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1